Please login to the form below

Not currently logged in
Email:
Password:

mergers and acquisitions

This page shows the latest mergers and acquisitions news and features for those working in and with pharma, biotech and healthcare.

Abingworth raises $315m to expand hunt for promising biotechs

Abingworth raises $315m to expand hunt for promising biotechs

The acquisitions of rare disease specialist Wilson Therapeutics by Alexion for $855m and of IFM Therapeutics – an immuno-oncology player – by Bristol-Myers Squibb for $1.3bn are recent successes for ... the firm which has seen 65 of its investments

Latest news

  • Daily Brief Daily Brief

    Deal done, Takeda looks to marketing and R&D savings of $1.4bn. ... Valeant’s years of buccaneering mergers and acquisitions, suspect business practices and allegations of fraud have left it saddled with debt and a pariah-like status in the industry.

  • Keeping it in the family pays dividends Keeping it in the family pays dividends

    They have been weathering economic and geo-political turmoil for generations. While industry wrestles with the fission sparked by the $420bn worth of mergers and acquisitions over the last three years, ... I wonder at the price tags on some partnership

  • 2017 pharma trends: Bon chance! 2017 pharma trends: Bon chance!

    Industry spent the last year or so preparing for a Clinton presidency, reflected in languishing biotech stock prices and a slowdown in the mergers and acquisitions craze that had previously gripped ... Republican leaders in Congress have indicated a

  • Pfizer rides out Sanofi and confirms $14bn Medivation takeover Pfizer rides out Sanofi and confirms $14bn Medivation takeover

    talazoparib, which is in phase III trials in BRCA-positive breast cancer, and brain cancer candidate pidilizumab. ... and a claimed market share of 51% in the prostate cancer hormonal therapy market.

  • Xarelto leads the charge at Bayer Xarelto leads the charge at Bayer

    performance in crop science and animal health, while net income grew almost 16% to 2.89bn. ... of the year, and expects division to post sales of more than 16bn for the full-year.

More from news
Approximately 8 fully matching, plus 66 partially matching documents found.

Latest Intelligence

  • Change in the pharma industry is inevitable Change in the pharma industry is inevitable

    succeeds. A high proportion (88%) of change initiatives fail. A similar proportion of business strategies, mergers and acquisitions suffer the same fate. ... However, the bad news is that countless research has clearly demonstrated that only 10-30% of

  • Deal Watch March 2017 Deal Watch March 2017

    By contrast, as well as five company acquisitions, there are a couple of product acquisitions in our Top 20, which might start to explain where the licences are going. ... Among the company acquisitions, Sartorius paid $320m in cash to acquire the

  • Deal Watch February 2017 Deal Watch February 2017

    Such a shareholder revolt seems more akin to what we have seen previously for company acquisitions rather than for a licensing transaction. ... Future deals to look out for? Looking ahead there are likely to be some further significant acquisitions in

  • Deal Watch January 2017 Deal Watch January 2017

    With a headline value of $125m this includes an upfront, option, equity and R&D funding. ... 250. Vertex. Merck KGaA. Collaboration. VX 970 VX 803 and 2 others ATR inhibitors.

  • Deal Watch December 2016 Deal Watch December 2016

    Of the 39 deals 17 were acquisitions, across a wide range of health care areas, from delivery technology to blood screening products, via OTC, surgical products and medical marijuana. ... And of these acquisitions 14 of them are paid-up - only three are

More from intelligence
Approximately 12 fully matching, plus 59 partially matching documents found.

Latest appointments

  • Ipsen bolsters leadership team Ipsen bolsters leadership team

    Ipsen bolsters leadership team. Ivana Magovcevic-Liebisch and Régis Mulot join the biopharma. ... With expertise in corporate partnering, mergers and acquisitions, pipeline and product portfolio development, legal and IP strategy, Magovcevic-Liebisch

  • IRX Therapeutics appoints Luba Greenwood to its board IRX Therapeutics appoints Luba Greenwood to its board

    Her career has spanned leadership roles in venture investing, business development, mergers and acquisitions, law, consulting and operations. ... Prior to that, she served as senior mergers and acquisitions counsel at Pfizer.

  • Apeiron bolsters management board Apeiron bolsters management board

    Apeiron bolsters management board. Peter Llewellyn-Davies joins as its CFO and CBO. ... With more than 25 years’experience in initial public offerings, mergers and acquisitions, as well as licensing and financial transactions in the chemical, biotech

  • Sobi appoints Torbjorn Hallberg as general counsel Sobi appoints Torbjorn Hallberg as general counsel

    He arrives at Sobi will more than 15 years’experience covering licensing, mergers and acquisitions at pharma groups such as  Ferring and Nycomed. ... Carin Dahlquist (an acting role), head of EMENA Hege Hellström and head of North America Rami Levin.

  • Paolo Carli appointed as head of MEA at Merck Paolo Carli appointed as head of MEA at Merck

    Carli joined Merck in 2009 as a member of the mergers and acquisitions team in Darmstadt, Germany, where he participated in the execution of transactions for the group. ... Our innovative treatment options and sustainable commitment for patients will

More from appointments
Approximately 0 fully matching, plus 28 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 4 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
CMR

Specialising in medical device market research, our approach is people-centric and we thrive on making connections with clients and research...

Latest intelligence

Developing advocacy in the pharmaceutical industry.
The importance of advocacy programmes...
GDPR and events. What does the pharma industry need to know?
Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
Digital trends in B2B sales - how far behind is Pharma?
The modern approach to B2B sales is data-driven, and enabled by digital tools....

Infographics